COVID-19 ve Endokrinolojik Etkileri

Abstract

The COVID-19 pandemic has created new and unprecedented difficulties in the follow-up and treatment of patients with endocrine disorders. For instance, patients with diabetes have a higher risk of severe disease when they are infected with SARS-CoV-2. Another example is the higher incidence of clinical presentations associated with diabetes such as insulin resistance, diabetic ketoacidosis (DKA), and hyperosmolar hyperglycemic state in patients with COVID-19. While diabetes has been showing a terrifying incidence all over the world, it was also associated with an increased mortality and morbidity risk in COVID-19 patients. This association can be stated as "the coincidence of two pandemics". Recommendations for type 2 diabetes mellitus (DM) management in the setting of this pandemic include social isolation, well hydration, tight self-glucose monitoring, and teleconference meetings. Target plasma glucose levels for inpatients with type 2 DM are 140-180 mg/dl as well as for all